Jay Caplan

Developing transformative therapies for Type 2 Diabetes @fractylhealth | X opinions/posts are my own.

[Jay Caplan @jdcaplan]

@markkaplan20 @bryan_johnson https://t.co/pjGeGzgTCB

[Shailendra Singh @shailsingh]

Looking forward @DDWMeeting.
Exciting parts of #DDW is seeing innovative technologies that have the potential to truly change patient outcomes

Check out @FractylHealth Duodenal Mucosal Resurfacing (DMR) — science, actual procedure, and what lies ahead in metabolic endoscopy

[Daniel J Drucker @DanielJDrucker]

People with #T1D deserve P3 clinical trials to study the cardioprotective and kidney-sparing actions of GLP-1 medicines https://t.co/k8z3e1NQci

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

My essay in the Sunday Washington Post: “A viral infection can have devastating effects. I experienced this firsthand.” @AEIecon @PostOpinions

https://t.co/4jximud8Hw

[Dr. Marty Makary @DrMakaryFDA]

FDA cannot verify the quality, safety, or efficacy of non-FDA approved drugs. https://t.co/0UJhH4BGfH

[Jay Caplan @jdcaplan]

@ohadhammer Love the slide. Thanks for sharing. Totally agree that patient convenience and tolerability will become key differentiators.

[Jay Caplan @jdcaplan]

@FractylHealth @washingtonpost @Harithr Full article available from Eric Topol at

[Eric Topol @EricTopol]

A one-shot gene therapy to make a lifetime's worth of GLP-1 (like Ozempic) @FractylHealth. But it requires direct injection to the pancreas and there are lots of unknowns. A clinical trial is starting soon.
Front page @washingtonpost today
gift link https://t.co/jcG5GrzPSL

[Jay Caplan @jdcaplan]

@GilesYeo @BBCRadio4 @BBCSounds Looking forward to the podcast here in the US

[Jay Caplan @jdcaplan]

@doctorsaluja @cristinatejerap @DiabetesCareADA https://t.co/dV3ZBKakAf

[Daniel J Drucker @DanielJDrucker]

Joel Habener @MassGeneralNews @Harvard at one of the lab social gatherings in the mid 1980s with one of the labs talented research fellows, currently the President of @Penn Larry Jameson

[Daniel J Drucker @DanielJDrucker]

Joel Habener pioneer in molecular biology, mentor, led foundational research that discovered a hormone dubbed GLP-1, which would later become the key ingredient in Ozempic and Mounjaro ⁦@MassGeneralNews⁩ ⁦@TheEndoSociety⁩ ⁦@Harvard⁩ https://t.co/dOLbjcuE0B

[Prof Kamlesh Khunti @kamleshkhunti]

📉 Our comprehensive review of Medication Adherence published in @DiabetologiaJnl

Non-adherence affects ~38% of people T2 diabetes,

Leads to higher HbA1c, more micro/macrovascular complications, hospitalisations, mortality, and major healthcare costs.

🔍 Causes span patient, socioeconomic, condition-related & system factors.

💊 Effective strategies: pharmacist-led care, fixed-dose combinations, and tailored, multifaceted interventions.

Tech & motivational tools show mixed results.

🔑 Personalised, scalable solutions are urgently needed. #T2D #DiabetesCare #MedAdherence

Led by Patrick Highton

https://t.co/HucsOrnl9Z

With @mark_funnell @PankajLeicester @LeeLingLim1 @scelee1 @frazac

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

12 former commissioners of the FDA came together to write a Perspectives piece for the New England Journal of Medicine; raising our concerns about recent changes to vaccine approval policy at the FDA and its implications for patients and public health.

[Jay Caplan @jdcaplan]

@BevTchangMD In the Surmount-4 trial, all patients received regular lifestyle counseling sessions delivered by a dietitian or qualified health care professional, focused on healthy, balanced meals with a 500-kcal/d deficit, and at least 150 min/wk of physical activity.

[Jeremy Shane @jeremylshane]

Fantastic @DKThomp podcast with Drs. @seeleyrj and David Alessio (@DukeMedSchool) on #GLP1 - what they do, how, & current thinking on why they have such broad effects on metabolism & inflammation. https://t.co/43Co3UA2zR

[Jay Caplan @jdcaplan]

@Maratosflier @DanielJDrucker @CellCellPress https://t.co/cQFYyqc4pv put a damper on this approach

[Chris Thompson, MD @MetabolicEndo]

Honored to join the Board of Fractyl Health at such a pivotal moment. Revita® is advancing through late-stage development, and Rejuva® is preparing for first-in-human studies. Fractyl is redefining how we treat obesity and type 2 diabetes by addressing root causes, not just symptoms. Excited to help shape this next chapter.

[Harith Rajagopalan @Harithr]

Welcoming @MetabolicEndo and Ian Sheffield to our Board marks an important moment for Fractyl. Their expertise in pioneering new approaches to obesity care and in building healthcare businesses with lasting impact will help guide us through this next stage of growth.

I’m also grateful to Amy Schulman for her service and leadership on our Board, and for helping position Fractyl to seize the opportunities ahead.

Looking forward to the journey as we continue advancing Revita® and Rejuva® toward our goal of transforming metabolic care.

$GUTS #FractylForward

Revita® is for Investigational Use Only in the U.S. under Federal law. Rejuva® is in preclinical development and has not yet been assessed by regulatory agencies.

[Daniel J Drucker @DanielJDrucker]

Happy special birthday to my friend and colleague the incomparable Jens Juul Holst @UCPH_Research @Metabolcenter @EASDnews @uni_copenhagen @novonordiskfond

[Kevin Hall @KevinH_PhD]

For the rest of July, folks in the UK get 25% off when they preorder Food Intelligence (my book with @juliaoftoronto) at @Waterstones. https://t.co/ZQ9Pk4lx4C